Skip to content

Study · Non-randomized trial · n = 71 · 2026

6 results

Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.

Yen Y, Zhang Q, Yin S, Pu Y, Song K, Song X, Shen X, Wan Q, Zhao R, Zhang G, Cheng Z, Widjaja J, Chen H, Chen Y

BMC medicine22 Jan 2026Cited by 4 (Europe PMC)

PMID41572274 (opens in a new tab)PMCIDPMC12910975 (opens in a new tab)DOI10.1186/s12916-026-04648-8 (opens in a new tab)PepBankPUB-41572274
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with obesity, once-weekly semaglutide gave a mean total weight loss of 11.3% at 12 months, significantly less than sleeve gastrectomy (28.6%).

    In plain wordsIn adults with obesity, semaglutide led to weight loss at 12 months, but less than sleeve gastrectomy surgery.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage total weight loss at 12 months
    Study

    n = 71

    Comparator
    Sleeve gastrectomy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeks (planned)As given in this study (human).

    Measurements

    %TWL
    11.3%
    semaglutide, 12 months
    %TWL
    28.6%
    sleeve gastrectomy, 12 months

    Source sentences

    Summary
    SG achieved significantly greater weight loss at all time points. At 12 months, mean %TWL was 28.6% for SG versus 11.3% for semaglutide (p < 0.001).
    2 context sentences
    Summary · context
    Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making.
    Summary · context
    Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with obesity, mean BMI fell from 32.0 to 28.4 kg/m2 with semaglutide, a smaller fall than with sleeve gastrectomy.

    In plain wordsIn adults with obesity, semaglutide lowered BMI, but by less than sleeve gastrectomy surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change at 12 months
    Study

    n = 71

    Comparator
    Sleeve gastrectomy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeks (planned)As given in this study (human).

    Measurements

    BMI
    32 kg/m2
    semaglutide, baseline
    BMI
    28.4 kg/m2
    semaglutide, follow-up

    Source sentences

    Summary
    Mean BMI decreased from 32.7 ± 2.8 to 23.8 ± 2.6 kg/m2 in the SG group and from 32.0 ± 2.6 to 28.4 ± 4.0 kg/m2 in the semaglutide group (p < 0.001).
    2 context sentences
    Summary · context
    Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making.
    Summary · context
    Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with obesity, sleeve gastrectomy was associated with greater reductions in triglycerides than semaglutide.

    In plain wordsIn adults with obesity, sleeve gastrectomy surgery lowered triglycerides more than semaglutide did.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglycerides
    Study

    n = 71

    Comparator
    Sleeve gastrectomy
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeks (planned)As given in this study (human).

    Source sentences

    Summary
    Both groups demonstrated metabolic improvements, but SG was associated with greater reductions in triglycerides and greater increases in high-density lipoprotein cholesterol (HDL-C).
    2 context sentences
    Summary · context
    Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making.
    Summary · context
    Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with obesity, sleeve gastrectomy was associated with greater increases in HDL-C than semaglutide.

    In plain wordsIn adults with obesity, sleeve gastrectomy surgery raised HDL cholesterol more than semaglutide did.

    Peptide
    Semaglutide
    Outcome
    IncreaseHDL cholesterol
    Study

    n = 71

    Comparator
    Sleeve gastrectomy
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeks (planned)As given in this study (human).

    Source sentences

    Summary
    Both groups demonstrated metabolic improvements, but SG was associated with greater reductions in triglycerides and greater increases in high-density lipoprotein cholesterol (HDL-C).
    2 context sentences
    Summary · context
    Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making.
    Summary · context
    Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with obesity who stopped semaglutide after 6 months, mean weight rose from 74.6 to 83.2 kg by 12 months.

    In plain wordsIn adults with obesity who stopped semaglutide after 6 months, body weight went back up by 12 months.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight change after stopping semaglutide at 12 months
    Study

    n = 25

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeks (planned)As given in this study (human).

    Measurements

    Body weight
    74.6 kg
    at discontinuation
    Body weight
    83.2 kg
    12 months

    Source sentences

    Summary
    Among patients who discontinued semaglutide after 6 months (n = 25), mean weight increased from 74.6 ± 11.3 to 83.2 ± 12.3 kg by 12 months, with 32% regaining to baseline weight or higher.
    2 context sentences
    Summary · context
    Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making.
    Summary · context
    Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference.
  6. 06HumanNon-randomized trialEfficacy outcome

    In adults with obesity who stopped semaglutide after 6 months, 32% regained to baseline weight or higher by 12 months.

    In plain wordsIn adults with obesity who stopped semaglutide after 6 months, about a third regained their starting weight or more by 12 months.

    Peptide
    Semaglutide
    Outcome
    IncreaseRegain to baseline weight or higher after stopping semaglutide
    Study

    n = 25

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeks (planned)As given in this study (human).

    Measurements

    Regained to baseline weight or higher
    32%
    after discontinuation

    Source sentences

    Summary
    Among patients who discontinued semaglutide after 6 months (n = 25), mean weight increased from 74.6 ± 11.3 to 83.2 ± 12.3 kg by 12 months, with 32% regaining to baseline weight or higher.
    2 context sentences
    Summary · context
    Adults with obesity were allocated to SG (n = 36) or once-weekly semaglutide (n = 35) based on shared decision-making.
    Summary · context
    Semaglutide was administered for a planned duration of 24 weeks, after which continuation or discontinuation was determined by patient preference.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.